医学
髓系白血病
造血干细胞移植
移植
疾病
微小残留病
重症监护医学
环磷酰胺
肿瘤科
造血细胞
移植物抗宿主病
白血病
内科学
干细胞
免疫学
造血
化疗
生物
遗传学
作者
Juan Montoro,Aitana Balaguer‐Roselló,Jaime Sanz
出处
期刊:Current Opinion in Oncology
[Ovid Technologies (Wolters Kluwer)]
日期:2023-08-30
卷期号:35 (6): 564-573
被引量:1
标识
DOI:10.1097/cco.0000000000000992
摘要
This review highlights recent advancements in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with acute myeloid leukemia (AML).Important improvements have been observed throughout the allo-HSCT procedure and patient management. Universal donor availability and reduced risk of graft-versus-host disease (GVHD) have been achieved with the introduction of posttransplant cyclophosphamide for GVHD prophylaxis. It has contributed, together with advances in conditioning regimens, GVHD treatment and supportive care, to a reduced overall toxicity of the procedure. Relapse is now the most frequent cause of transplant failure. With increased knowledge of the biological characterization of AML, better prediction of transplant risks and more profound and standardized minimal residual disease (MRD) monitoring, pharmacological, and immunological strategies to prevent relapse are been developed.Allo-HSCT remains the standard of care for high-risk AML. Increased access to transplant, reduced toxicity and relapse are improving patient outcomes. Further research is needed to optimize MRD monitoring, refine conditioning regimens, and explore new GVHD management and relapse prevention therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI